GWLL Stock Overview
Focuses on nutraceutical and dietary supplements business in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Goldenwell Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$0.33 |
| 52 Week Low | US$0.059 |
| Beta | 2.72 |
| 11 Month Change | 0% |
| 3 Month Change | -11.11% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| GWLL | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 2.2% |
| 1Y | n/a | -12.0% | 31.6% |
Return vs Industry: Insufficient data to determine how GWLL performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how GWLL performed against the US Market.
Price Volatility
| GWLL volatility | |
|---|---|
| GWLL Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GWLL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GWLL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Shuang Liu | n/a |
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI—bovine cardiac vascular active peptide; Double Proline AG – 3D active collagen peptide; cartilage peptide, a type II collagen peptide; Se Plus tablets and sugar master tablets. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech, Inc. Fundamentals Summary
| GWLL fundamental statistics | |
|---|---|
| Market cap | US$19.80m |
| Earnings (TTM) | -US$137.10k |
| Revenue (TTM) | US$939.00 |
Over9,999x
P/S Ratio-144.4x
P/E RatioIs GWLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GWLL income statement (TTM) | |
|---|---|
| Revenue | US$939.00 |
| Cost of Revenue | US$531.00 |
| Gross Profit | US$408.00 |
| Other Expenses | US$137.51k |
| Earnings | -US$137.10k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0014 |
| Gross Margin | 43.45% |
| Net Profit Margin | -14,600.85% |
| Debt/Equity Ratio | 0% |
How did GWLL perform over the long term?
See historical performance and comparison